Quadruple Therapy with Medications Containing Either Rufloxacin or Furazolidone as a Rescue regimen in the Treatment of Helicobacter pylori-Infected Dyspepsia Patients: A Randomized Pilot Study

Helicobacter

Volumn 16, Issue 4, 2011, Pages 284-288

  Gu, Li Yang ^a   Lin, Wei Wei ^a   Lu, Hong ^a,b   Chen, Xiao Yu ^b   Ge, Zhi Zheng ^a,b   Li, Xiao Bo ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute of Digestive Disease   (China)

Author keywords

Eradication; Helicobacter pylori; Quadruple therapy; Rescue

Indexed keywords

BISMUTH CITRATE; CARBON 13; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RUFLOXACIN;

ADULT; AGED; ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HEADACHE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CHINA; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 79960438847     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00848.x     Document Type: Article

References (29)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
2. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008;148:923-31.
3. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
4. Wang ZH, Xiong GS, Wu SM. Levofloxacin-based triple regimens in rescue the treatment for H. pylori eradication: a meta-analysis. Chin J Dig 2007;27:534-7 (Chinese).
5. Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006;11:243-9.
6. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006;11:237-42.
7. Glocker E, Stueger H, Kist M. Quinolone resistance in Helicobacter pylori in Germany. Antimicrob Agents Chemother 2007;51:346-9.
8. Gisbert JP, Calvet X, Gomollon F, Sainz R. Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med Clin (Barc) 2005;125:301-16.
9. Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6.
10. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008;14:5385-402.
11. Buzás GM, Józan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2007;22:1571-81.
12. Xiao SD, Liu WZ, Xia DH, et al. The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori- a randomized double-blind placebo-controlled clinical trial. Hepatogastroenterology 1990;37:503-6 (Chinese).
13. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002;7:225-31.
14. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002;16:1277-82.
15. Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs: a comparative review. Scand J Gastroenterol Suppl 1989;169:70-80.
16. Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63:2769-802.
17. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
18. Wang ZH, Xiong GS, Wu SM. The study of levofloxacin-based quadruple regimen as rescue therapy for Helicobacter pylori infection. Chin J Gastroenterol Hepatol, 2006;15:38-9.
19. Wong WM, Gu Q, Chu KM, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7.
20. Gao W, Cheng H, Hu FL, et al. The evolution of Helicobacter pylori antibiotics resistance over 10years in Beijing, China. Helicobacter 2010;15:460-6.
21. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010;16:5118-21.
22. Lee CC, Lee VWY, Chan FKL, Ling TKW. Levofloxacin-resistant Helicobacter pylori in Hong Kong. Chemotherapy 2008;54:50-3.
23. Imbimbo BP, Broccali GP, Cesana M, Crema F, Attardo-Parrinello G. Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob Agents Chemother 1991;35:390-3.
24. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19.
25. Wise R, Johnson J, O'Sullivan N, Andrews JM, Imbimbo BP. Pharmacokinetics and tissue penetration of rufloxacin, a long-acting quinolone antimicrobial agent. J Antimicrob Chemother 1991;28:905-9.
26. Mattina R, Cocuzza CE, Cesana M, et al. Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Infection 1993;21:106-11.
27. Wise R, Andrews JM, Matthews R, Wolstenholme M. The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother 1992;29:649-60.
28. Kisicki JC, Griess RS, Ott CL, et al. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers. Antimicrob Agents Chemother 1992;36:1296-301.
29. Ravizzola G, Pinsi G, Pirali F, et al. Rufloxacin (MF 934): in vitro and in vivo antibacterial activity. Drugs Exp Clin Res 1989;15:11-5.